Latest Rubicon Research stock price
Rubicon Research P/E Ratio
RUBICON • P/E ratio trend, valuation band, and sector comparison — all formatted to support journal-based trading review.
Current P/E Ratio
81.31
High Valuation
Very High - High growth expectations or significantly overvalued
Current Valuation Metrics
P/E Ratio
81.31
Current Price
₹670.35
EPS (TTM)
₹8.82
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
57.05
Sector Median
35.38
Sector Rank
#11 of 88
Sector Percentile
12.5%
Earnings Breakdown (TTM)
TTM EPS
₹10.23
Sept 2025
₹3.49
Jun 2025
₹2.81
Key P/E Ratio Insights for Rubicon Research
- Stock appears overvalued with PE of 81.31, suggesting caution for new investments
- Trading at premium to sector average PE of 57.05
View the RUBICON equity price for detailed stock performance.
Related Pages for Rubicon Research
Additional stock information and data for RUBICON
Sector P/E Ratio Comparison
Comparing Rubicon Research with other companies in Healthcare sector
Sector Average
57.05
Sector Median
35.38
Lowest P/E
9.01
Highest P/E
515.32
Companies
88
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Fermenta Biotech | FERMENTA | 9.01 | ₹1,010 | Low |
| Natco Pharma | NATCOPHARM | 10.8 | ₹17,006 | Low |
| Mohini Health & Hygiene | MHHL | 11.84 | ₹69 | Low |
| Lincoln Pharmaceuticals | LINCOLN | 12.02 | ₹974 | Low |
| QMS Medical Allied Servi… | QMSMEDI | 12.82 | ₹177 | Low |
| Take Solutions | TAKE | 13.15 | ₹638 | Low |
| Venus Remedies | VENUSREM | 14.27 | ₹995 | Low |
| Royal Sense | ROYAL | 14.5 | ₹96 | Low |
| Bliss GVS Pharma | BLISSGVS | 16.62 | ₹1,973 | Moderate |
| RPG Life Sciences | RPGLIFE | 17.94 | ₹3,861 | Moderate |